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Vesicular Rab5 (green) colocalizes with 
Huntingtin (red).
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equal aging
S
cientists have hypothesized that 
aneuploidy could be a driving factor in 
aging. On   page 529  , Baker et al. report 
evidence to the contrary.
Using a mutation series in the BubR1 mitotic 
checkpoint protein, the researchers previously 
showed that as the amount of functional protein 
decreased, aneuploidy increased, as did the 
rate of aging. To determine whether the correla-
tion was causal, Baker et al. now compared the 
BubR1 mutants to mice carrying mutations in two 
other mitotic checkpoint genes, Bub3 and Rae1. 
The double mutant animals had signiﬁ  cantly more 
aneuploidy than did the BubR1 mice. However, 
the double mutants reached old age at 18 to 24 
months, which is about four months earlier than 
wild-type controls, whereas the BubR1 animals 
were completely aged at just ﬁ  ve months.
There was a correlation in all strains tested 
between the rate of aging, cell senescence, and 
expression of the Rb and p53 stress response 
proteins. Both mutant strains, though, had nearly 
the same DNA repair capacity as did the wild-
type animals, which leaves open the question as 
to what triggers the p53 pathway.
The severity of the mitotic checkpoint de-
fect did not correlate with the rate of aging, 
and not all checkpoint genes accelerated ag-
ing when mutated. That may mean that the 
checkpoint proteins BubR1, Bub3, and Rae1 
are working through a nonmitotic pathway to 
trigger p53 and senescence, and ultimately to 
control aging.
<d oi >1 0.10 83 /j cb. 17 24 iti2</ do i><a id >jcb 17 24 it i2 </ai d><au>Rabiya S. Tuma</au><cor>rabiya@nasw.org</cor>A slow death
N
eurodegenerative diseases induce a slow form of cell death that is 
inconsistent with either apoptosis or necrosis. Hoshino et al. ( page 589 ) 
describe a novel slow form of cell death caused by transcriptional 
repression, a dysfunction associated with neurons in the polyglutamine diseases.
Primary neurons grown in culture in the presence of α-amanitin, a chemical 
repressor of transcription, survived for fi  ve days, whereas treated nonneuronal 
cells underwent apoptotic death within 12 hours. When the neurons fi  nally did 
die, their demise did not resemble apoptosis, necrosis, or autophagy, in terms 
of morphology, biochemical characteristics, or DNA breakdown.
YAP, a cotranscription factor that works with p73 to induce transcription 
of proapoptotic genes, was highly expressed in cells undergoing this slow 
transcriptional repression induced atypical death (TRIAD). However, the 
forms of YAP protein expressed in these neurons, YAP∆Cs, lacked the 
transcriptional activation domain, and thus acted as dominant-negative 
mutants that blocked expression of target genes.
siRNAs directed against YAP∆Cs led to rapid death in primary neurons 
exposed to α-amanitin, whereas overexpression of YAP∆Cs protected 
nonneuronal cells from apoptosis triggers.
YAP∆Cs were detected in neurons in brain sections from wild-type and 
Huntington disease model mice, and in samples from the brains of human 
Huntington disease patients. Relative to controls, mutant mice expressed a 
greater proportion of YAP∆Cs versus full-length YAP. Moreover, overexpression 
of YAP∆Cs slowed cell death in transgenic fl  y neurons expressing mutant 
huntingtin protein. Still not clear, however, is whether YAP∆Cs slow down 
cell death in humans suffering from polyglutamine diseases.
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O
n   page 605  , Pal et al. report that Huntingtin (Htt) and its associated 
protein HAP40 are part of the machinery used by Rab5 to control 
switching between microtubules and actin ﬁ  laments. The data may 
explain why vesicle motility is disrupted in Htt mutant cells.
When Pal et al. went looking for Rab5 effector proteins by afﬁ  nity chro-
matography, they isolated HAP40 and Htt. Biochemical analysis showed 
that HAP40 acts as a bridge between Rab5 and Htt in a GTP-dependent 
manner. Excess HAP40 drives the vesicles 
off microtubules and onto actin ﬁ  laments, re-
ducing the vesicles’ motility. Addition of an 
antibody against Htt relieved the transport 
restriction, suggesting that Htt neg-
atively regulates the link between 
endosome and microtubules.
Surprisingly, HAP40 expres-
sion was tenfold higher in cells 
isolated from Huntington patients 
The muscles of a 19-month-old mutant look like those 
of a 35-month-old wild-type animal.
as compared with cells from healthy volunteers. Such Htt mu-
tant cells had reduced endocytosis and endosome motility.
In wild-type cells, a small amount of Htt protein on en-
dosomes works with HAP40 and Rab5 to regulate motility; 
however, the up-regulation of HAP40 in Huntington disease 
cells is necessary and sufﬁ  cient to arrest endosome motility. 
The team now wants to know just how restricted endosome 
motility might impact Huntington disease pathology and why 
HAP40 is overexpressed in Htt mutant cells.
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